— Know what they know.
Not Investment Advice

PROF

Profound Medical Corp.
1W: +6.4% 1M: -18.6% 3M: -20.7% YTD: -24.0% 1Y: -14.5% 3Y: -42.7% 5Y: -73.6%
$6.55
+0.73 (+12.54%)
 
NASDAQ · Healthcare · Medical - Devices · $176.1M · Alpha Radar Strong Sell · Power 29
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$176.1M
52W Range3.76-8.95
Volume602,377
Avg Volume233,652
Beta0.39
Dividend
Analyst Ratings
6 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOArun Swarup Menawat
Employees142
SectorHealthcare
IndustryMedical - Devices
IPO Date2019-10-29
2400 Skymark Avenue
Mississauga, ON L4W 5K5
CA
16474761350
About Profound Medical Corp.

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Menawat Arun Swarup P-Purchase 12,027 $4.73 2025-05-16
Menawat Arun Swarup P-Purchase 10,003 $4.33 2025-05-15
HOFER MICHAEL S-Sale 40,000 $0.16 2012-12-20
HOFER MICHAEL P-Purchase 40,000 $0.15 2012-12-18
HOFER MICHAEL P-Purchase 500,000 $0.00 2012-06-19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms